Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Hypopharyngeal cancer
Stage/Subtype:  stage III hypopharyngeal cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 75 for your search:
Start Over
Radiation Therapy with Cisplatin, Docetaxel, or Cetuximab and Docetaxel after Surgery in Treating Patients with High-Risk Stage III-IV Squamous Cell Head and Neck Cancer
Status: Temporarily closed
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG-1216, NCI-2013-00500, NCT01810913
Cetuximab, EGFR Antisense DNA, and Radiation Therapy in Treating Patients With Stage III-IV Squamous Cell Cancer of the Head and Neck
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 06-121, NCI-2013-00329, NCT00903461
Combination Chemotherapy with or without Veliparib in Treating Patients with Stage IV Head and Neck Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: A091101, NCI-2012-02009, NCT01711541
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
Palbociclib and Cetuximab in Treating Patients with Squamous Cell Carcinoma of the Head and Neck
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201404139, NCI-2014-01079, 14-X031, NCT02101034
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-02, NCI-2015-00273, NCT02335918
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PLX108-14, NCI-2015-01614, KEYNOTE-103, NCT02452424
A Study to Investigate the Safety and Efficacy of Nivolumab and Nivolumab Plus Ipilimumab in Virus-associated Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-358, NCI-2015-01356, 2015-000230-29, NCT02488759
Pembrolizumab and Vorinostat in Treating Patients with Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9383, NCI-2015-01310, MK-3475, NCT02538510
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-06, NCI-2015-02086, NCT02543645
Docetaxel, Cisplatin, and Cetuximab in Treating Patients with Metastatic or Relapsed Head and Neck Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 16 and over
Trial IDs: ENT0033, NCI-2011-03271, 22329, SU-08222011-8290, NCT01437449
TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RF-3501, NCI-2014-01403, LAP116153, NCT01711658
Cisplatin and Radiation Therapy with or without Dose Boost in Treating Patients with Stage III-IV Head and Neck Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: UMCC 2013.062, NCI-2013-01978, 2013.062, HUM00074305, NCT02031250
Stereotactic Radiosurgery and Cetuximab with or without Docetaxel in Treating Patients with Recurrent Head and Neck Cancer Previously Treated with Radiation Therapy
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: 11-112, NCI-2014-01954, REN13090047, UPCI 11-112, NCT02057107
Docetaxel and Carboplatin with or without Low Dose Radiation Therapy in Treating Patients with Previously Untreated Locally Advanced Head and Neck Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-HN-24, NCI-2014-01913, NCT02126969
Radiation Therapy With Cisplatin or Docetaxel and Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 13-056, NCI-2014-01116, 13-056, PRO13080400, NCT02128906
Azacitidine in Measuring Tumor Response in Patients with HPV Positive or Negative Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 1404013771, NCI-2015-01437, NCT02178072
Radiation Therapy and Pembrolizumab in Treating Patients with Head and Neck Squamous Cell Carcinoma That Is Recurrent or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 1456GCC, NCI-2015-01783, HP-00061458, NCT02289209
Pembrolizumab in Treating Patients with Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201412118, NCI-2014-02626, 14-x330, NCT02296684
In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®
Status: Active
Phase: Phase II
Type: Treatment
Age: 14 and over
Trial IDs: ONC2014-001, NCI-2016-01295, NCT02423863
Paclitaxel and Carboplatin before Radiation Therapy with Paclitaxel in Treating HPV-Positive Patients with Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 19 and over
Trial IDs: CCRO022, NCI-2013-02394, 13-000915, NCT02048020
Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PM1183-B-005-14, NCI-2015-01172, NCT02454972
Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: A5481044, NCI-2015-01296, 2015-000515-41, PALATINUS, NCT02499120
Start Over